TMCnet News
Evogene Announces Filing of Annual Report on Form 20-FREHOVOT, Israel, March 30, 2023 /PRNewswire/ -- Evogene Ltd. (Nasdaq: EVGN) (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, today announced that it filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2022 with the Securities and Exchange Commission. The Annual Report on Form 20-F can be accessed on the Company's investor relations website https://evogene.com/investor-relations/ and on the SEC's website at http://www.sec.gov. The Company's security holders may request a hard copy of the Annual Report free of charge by visiting the Contact Us page of the Company's website. About Evogene Ltd. Evogene Ltd. (Nasdaq: EVGN, TASE: EVGN) is a computational biology company leveraging big data and artificial intelligence, aiming to revolutionize the development of life-science based products by utilizing cutting-edge technologies to increase the probability of success while reducing development time and cost. Evogene established three unique tech-engines - MicroBoost AI, ChemPass AI and GeneRator AI. Each tech-engine is focused on the discovery and development of products based on one of the following core components: microbes (MicroBoost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI). Evogene uses its tech-engines to develop products through strategic partnerships and collaborations, and its five subsidiaries including:
View original content:https://www.prnewswire.com/news-releases/evogene-announces-filing-of-annual-report-on-form-20-f-301786247.html SOURCE Evogene |